Diabetic Ketoacidosis-Associated Stroke in  Children and Youth by Foster, Jennifer Ruth et al.
SAGE-HindawiAccess to Research
Stroke Research and Treatment
Volume 2011, Article ID 219706, 12 pages
doi:10.4061/2011/219706
Review Article
DiabeticKetoacidosis-Associated Strokein Children andYouth
JenniferRuthFoster,1,2 GavinMorrison,1 andDouglasD. Fraser1,2,3,4,5,6
1Critical Care Medicine and Paediatrics, University of Western Ontario, London, ON, Canada N6A 5W9
2Children’s Health Research Institute, London, ON, Canada N6C 2V5
3Centre for Critical Illness Research, London, ON, Canada N6C 2V5
4Clinical Neurological Sciences, University of Western Ontario, London, ON, Canada N6A 3K7
5Physiology and Pharmacology, University of Western Ontario, London, ON, Canada N6A 3K7
6Translational Research Centre, London, ON, Canada N6C 2V5
Correspondence should be addressed to Jennifer Ruth Foster, jennifer.foster@lhsc.on.ca
Received 8 October 2010; Revised 12 November 2010; Accepted 4 December 2010
Academic Editor: Halvor Naess
Copyright © 2011 Jennifer Ruth Foster et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Diabetic ketoacidosis (DKA) is a state of severe insulin deﬁciency, either absolute or relative, resulting in hyperglycemia and
ketonemia. Although possibly underappreciated, up to 10% of cases of intracerebral complications associated with an episode
of DKA, and/or its treatment, in children and youth are due to hemorrhage or ischemic brain infarction. Systemic inﬂammation
is present in DKA, with resultant vascular endothelial perturbation that may result in coagulopathy and increased hemorrhagic
risk. Thrombotic risk during DKA is elevated by abnormalities in coagulation factors, platelet activation, blood volume and ﬂow,
and vascular reactivity. DKA-associated cerebral edema may also predispose to ischemic injury and hemorrhage, though cases of
stroke without concomitant cerebral edema have been identiﬁed. We review the current literature regarding the pathogenesis of
stroke during an episode of DKA in children and youth.
1.Introduction
Type 1 diabetes mellitus (T1DM) is a common autoimmune
condition that often presents in childhood and may be
complicated by episodes of diabetic ketoacidosis (DKA).
DKA is a state of severe insulin deﬁciency, either absolute
or relative, resulting in hyperglycemia, ketonemia, acidemia,
and systemic inﬂammation. Compared with adults, episodes
of DKA in children carry a higher risk of morbidity and
mortality. This is predominantlyattributableto intracerebral
complications [1–5], which occur in 3–10 pediatric patients
per 1000 cases of DKA [6]. The most common intracerebral
complication of DKA is cerebral edema (DKA-CE), which
results in the death of 21–24% of aﬀected patients, and sig-
niﬁcant morbidity in a further 10–35%[6–8]. Less common,
and perhaps underappreciated, is the risk of acute ischemic
or hemorrhagic stroke during the acute DKA episode. It has
been estimated based on case series that approximately 10%
of intracerebral complications of DKA are due to hemor-
rhage or ischemic brain infarction [4, 5]. While some cases
of brain infarction may arise secondary to DKA-CE-induced
herniation with resultant vessel occlusion, it has become
clear that not all cases of stroke in DKA are associated with
cerebraledema (CE).As thepresentation ofstroke associated
with DKA may mimic that of CE but requires diﬀerent
management strategies, it is imperative for the clinician to
be cognizant of this potential complication. This review will
examine the etiology and pathogenesis of stroke associated
with episodes of DKA in children and youth (age <20).
While Type 2 diabetes mellitus is becoming more commonly
recognized inthepediatric populationandmaypresentwith,
or be complicated by, DKA [9, 10], cerebral thrombosis-
associated stroke has not been reported with Type 2 diabetes
mellitus. Thus, the review focuses on children with T1DM.
2.PathogenesisofIschemic Stroke
Diabetes mellitus is a known independent risk factor for
ischemic stroke, conferring two times the risk of an ischemic
event in adults compared to the nondiabetic population2 Stroke Research and Treatment
[11, 12]. There are several characteristics of DKA that place
children at higher risk of cerebral ischemia. The reported
cases on DKA-associated stroke in children and youth are
presented in Table 1.
2.1. DKA as a Systemic Inﬂammatory Illness. DKA is more
than simply a deterioration of glucose metabolism; it is also
associated with a systemic inﬂammatory response character-
ized by vascular endothelial injury and coagulopathy. The
inﬂammatory state accompanying DKA is characterized by
elevated levels of inﬂammatory markers (CRP), cytokines
(IL6, IL1β,T N F α), and complement activation [26–30]. It
is likely that the oxidative stress induced by hyperglycemia
and ketosis [31] contributes to this inﬂammatory reaction
and results in diﬀuse vascular injury. Evidence of vascular
endothelial injury can be seen in pretreatment subclinical
CE [1], pulmonary interstitial edema [2, 23, 24, 32],
disseminated intravascular coagulation (DIC) [13, 16, 33,
34], and elevated levels of thrombomodulin [35].
Chronically, the vascular endotheliumis a primary target
of the abnormal glycemic metabolism in T1DM [27]. Chil-
dren with T1DM may be at risk of a chronic state of inﬂam-
mationandendothelialactivationoutsideofepisodeofDKA.
Children within 1 year of diagnosis have been reported to
have biochemical evidence of inﬂammation, with increased
levels of both serum prothrombin fragments and TNFα
comparedtochildren morethan 1yearpost-diagnosis and to
nondiabetic controls [36]. Furthermore, this report detailed
evidence of endothelial perturbation, characterized by levels
of von Willebrand Factor (vWF) and tissue plasminogen
activator (tPA) more than 2 standard deviations higher
than control. Another study found that the endothelial cell-
speciﬁc adhesion molecule, soluble endothelial leukocyte
adhesion molecule (sE-Selectin), was elevated in children
with T1DM compared to healthy controls, and positively
correlated with serum glucose concentration [37]. Analysis
of the coagulation system in adults with diabetes has also
identiﬁed abnormalities in many steps of the coagulation
system [38].
2.2. Abnormalities in the Coagulation Cascade. Two case
controlled studies [42, 43] found an increased rate (50%) of
clinically apparent deep venous thrombosis (DVT) in very
young children (less than 3 years) with DKA who required
femoral central venous catheter (CVC) insertion when
compared with age-matched nondiabetic controls (who
also underwent femoral CVC insertion). Comparatively, an
incidence rate of 1.5–18.3% has been described for clinically
or radiologically apparent femoral CVC-associated DVTs
in the PICU population [42, 44]. Although the propensity
for hypercoagulability in diabetes mellitus has not been
describedasaspeciﬁc isolatedriskfactorforDVT inchildren
[42], it is clear that the procoagulant mechanisms that place
children with an episode of DKAat risk of CVC-related DVT
may also act to increase the risk of stroke.
The inﬂammatory conditionseeninDKA,withendothe-
lial perturbation, predisposes to an acquired procoagulant
state [26]. While the majority of case studies of children
with DKA-associated stroke have not identiﬁed consistent,
generalized alterations in the coagulation system (Table 1),
these studies have mainly examined the coagulation system
at a single time point after identiﬁcation of a neurologic
abnormality. More systematic evaluation of coagulation
abnormalities during an episode of DKA requires longi-
tudinal consideration, both before and during therapeutic
intervention. Indeed, longitudinal studies in children [41]
and adults [35] with DKA have identiﬁed multiple coagula-
tion abnormalities, including increased platelet aggregation,
elevated levels of procoagulants, and decreased activity of
anticoagulants. Coagulation factors for which abnormalities
have been noted during DKA or its treatment in either
children or adults have been summarized (Table 2).
Examination of the coagulation factors of 7 adolescents
on presentation with DKA and at several time points
after initiation of DKA therapy demonstrated abnormalities
in Protein C, Protein S, plasma homocysteine, and von
Willebrand Factor (vWF) [41]. Protein C levels are initially
elevatedbutquicklydecreasetonormalwithDKAtreatment,
while Protein C activity is initially low and slowly normalizes
with treatment. Adult patients with T1DM have signiﬁcantly
lower protein C levels than controls [45]. Their protein C
levels are inversely related to glucose concentrations but
exhibit no relationship with glycosylated hemoglobin A
(HbA1c) levels. This latter ﬁnding suggests that acute, rather
than chronic, variations in blood glucose may determine the
response of Protein C, which may itself explain the normal
values found in most patients with DKA-associated stroke
(Table 1).
Plasma homocysteine is an important factor in
atherosclerosis and thrombosis [46] and also decreases
protein C activation [47]. Plasma homocysteine levels
in adolescents are elevated in DKA and gradually
normalize after insulin initiation [41]. The relatively
rapid homocysteine rise may result in the very gradual
normalization of protein C activity that has been observed.
In adolescents, Protein S antigen levels remain normal
during DKA while free protein S, the active anticoagulant,
is reduced and does not return to baseline with treatment
[41]. This is consistent with the ﬁnding that low levels of free
protein S are the result of increased levels of C4b-binding
protein in poorly controlled adult T1DM patients [30].
vWF is synthesized and secreted by endothelial cells,
facilitates platelet adhesion, and is a carrier protein for factor
VIII. High vWF levels are a marker of endothelial injury
and activation. In adolescents, vWF antigen and activity
are initially increased in DKA and decrease slowly with
DKA therapy [41]. Factor VIII concentration is also elevated
in adults with long-standing insulin-dependent diabetes
mellitus during an episode of DKA [48, 49]. The ﬁbrinogen
concentration remains normal throughout DKA and its
management [41]. However, ﬁbrinogen circulating in an
environment of high glucose can become hyperglycosylated
[50] with resulting ﬁbrin ﬁbers that are resistant to plasmin
degradation [51].
In 8 adults receiving a continuous subcutaneous insulin
infusion, researchers examined the eﬀects of infusion cessa-
tion for 4 hours [40]. All subjects entered early biochemical
DKA. Tests of ﬁbrinolytic activity after vascular stimulationStroke Research and Treatment 3
Table 1: Case reports of arterial ischemic stroke, cerebral venous thrombotic stroke, and hemorrhagic stroke associated with an episode of
DKA in children and youth.
Patient
number
Age
(year) Gender Pathologic ﬁndings Clinical Presentation Outcome Coagulation proﬁle Reference
number
Arterial Ischemic Stroke.
10 . 2 5 f e m a l e
Multiple small vessel
thrombi with edema
on autopsy
First presentation
diabetes, generalized
seizure, progressive
coma on admission
Death at 24 hours [13]
24f e m a l e
Infarction, right
posterior cerebral
artery distribution
First presentation
diabetes, decerebrate
posturing, acute
herniation
Slowly regained ability
to walk and
comprehend speech
Low protein C
normalized with
treatment, elevated
Factor VIII-vWF
complex, elevated
plasma and platelet
thromboxane B2
[14]
38m a l e
Infarction of left
thalamus,left
temporal lobe, B/L
occipital lobes
Decerebrate posturing Slow recovery
Low protein C
antigen,
normalized
[14]
4 10 unknown Basilar artery
thrombosis on CT
Restless, decreasing
LOC over 4.5 hours,
r e s p i r a t o r ya r r e s ta t7
hours
Persistent vegetative
state [4]
51 4 f e m a l e
CT edema and
infarction of left
lentiform nucleus,
thalami,B/L
peduncles
Headache,
deteriorating LOC.
Pupils midline, ﬁxed,
dilated after 12 hours
Mild left hemiparesis,
behavioral
disturbances
[15]
65m a l e
Infarction left
posterior cerebral
artery distribution,
geniculate nuclei, left
thalamus
First presentation
diabetes, generalized
seizure
Moderate left
hemiplegia
Low protein S,
elevated factor VIII
and factor V
[5]
76m a l e
Infarction B/L
anterior cerebral
artery distributions,
basal ganglia, left
cingulate gyrus
First presentation
diabetes, lethargy and
posturing of upper
extremities
Emotionally labile,
intellectual and motor
impairment
Low AT III antigen,
AT III functionally
normal,increased
platelet
aggregation
[5]
87m a l e
Ischemia in globus
pallidus, B/L
cingulate gyri.
Infarctions left
thalamus,right
medial occipital lobe.
No CT edema
First presentation
diabetes, decreased
level of consciousness
with incontinence,
stiﬀness, pupils poorly
reactive
Hemiplegia, normal
cognition, abnormal
behavior and aﬀect,
Decreased platelet
aggregation [5]
98m a l e
Infarction thalamus,
midbrain, basal
ganglia, cingulated
gyrus. No CT edema
First presentation
diabetes, unresponsive,
ﬂaccid, pupils dilated
Vegetative state Low aPTT (21
seconds) [5]
10 10 male
Infarction right
anterior cerebral
artery distribution,
left putamen, B/L
globus pallidus
First presentation
diabetes, decreased
LOC, left extensor
posturing, abnormal
papillary response
Severe focal neurologic
impairment [5]
11 6 female
Infarction proximal
left middle cerebral
artery, left basal
ganglia
First presentation
diabetes, irritability,
lethargy, right
hemiparesis, aphasia.
Had 2 mitral valve
thrombi
Regained speech,
residual right
hemiparesis
Normal
pro-thrombotic
studies
[6]4 Stroke Research and Treatment
Table 1: Continued.
Patient
number
Age
(year) Gender Pathologic ﬁndings Clinical Presentation Outcome Coagulation proﬁle Reference
number
12 18 female
Infarction right
commoncarotid
artery territory with
distal emboli in right
anterior and middle
cerebral arteries
First presentation
diabetes, left
hemiparesis 10 hours
after carotid artery
puncture
Moderate clinical
recovery [16]
Cerebral Venous Thrombosis.
13 5 female
Thrombosis of
straight sinus and
vein of Galen.
Infarction of basal
ganglia, thalamus
Confusion, decreased
LOC, rigidity, ﬁsting.
Signiﬁcant iron
deﬁciency anemia
Mild learning
diﬃculties
Normal clotting
screen and
thrombophilia
screen
[17]
14 11 male
Multiple areas of
infarction on MRI
without hemorrhage
or edema
Headache, nausea and
vomiting, acute
deterioration with
ﬁxed, dilated pupils.
Had DVT of right
superﬁcial femoral and
popliteal veins
Brain death
Decreased protein
C function (36%),
normalprotein S
and factor VIII, no
anticardiolipins.
Heterozygous
factor V Leiden
[18]
15 19 female Superior sagittal sinus
thrombosis
First presentation
diabetes. Anxiety
progressed to
psychosis, dysphasia,
left abducens palsy,
right inferior facial
palsy, tetraparCsis with
upper motor neuron
signs
Partial left abducens
paresis with diplopia
which resolved
coagulopathy
screen negative [19]
16 8 male
Vein of galen and
superior sagittalsinus
thrombosis. B/L
medial cerebral
hemisphere
infarctions
First presentation
diabetes, loss of
consciousness,sluggish
pupillary reaction,
fever
GCS remained 6 when
transferred to another
hospital
Low platelets,
decreased ATIII
(60.4%) increased
with treatment,
elevated D-dimer,
increased with
treatment
[20]
17 1.1 female
Left transverse sinus
thrombosis, no
infarction
First presentation of
thiamine-responsive
megaloblastic anemia,
associated with
nonimmune
insulin-dependent
diabetes. Right-sided
focal seizure
Normal neurologic
status
Prothrombotic
screening negative [16]
18 10 female
Thrombosis of
superior sagittal,
straight, right
transverse, right
sigmoid and proximal
posterior left
transverse sinuses
Headache, 6th cranial
nerve palsy day 3,
decreased level of
consciousness day 5
Recombinant tPA
thrombolysis, complete
recovery
Heterozygous
mutation of the
prothrombin gene
(G20210A)
[21]
Hemorrhagic infarction.
19 11 female
Multiple large, B/L
posterior temporal
lobe hematomas
Behavioral disturbance,
lethargy, progressed to
unresponsive, pupils
dilated and unreactive
Normal neurologic
exam [22]
20 1 unknown Subarachnoid
hemorrhage on CT
Sudden respiratory
arrest Died at 2 days [4]Stroke Research and Treatment 5
Table 1: Continued.
Patient
number
Age
(year) Gender Pathologic ﬁndings Clinical Presentation Outcome Coagulation proﬁle Reference
number
21 11 unknown Subarachnoid
hemorrhage on CT
Progressively
worsening neurologic
status
Death [4]
22 6.5 unknown
CT suggestive of
subarachnoid
hemorrhage
Severe headache and
restless. Pupils ﬁxed,
dilated at 3 hours,
r e s p i r a t o r ya r r e s ta t6
hours
Death [4]
23 9 female
Hemorrhagic
infarction right
caudate nucleus,
anterior limb of
internal capsule.
Non-hemorrhagic
infarction of B/L
thalami with edema
Ataxia, deteriorating
LOC, abnormal
respiratory pattern,.
Developed decorticate
posturing, right-sided
tonic seizure
Communication
disorder, asymmetric
spastic quadriparesis,
behavior disturbances.
[15]
24 9 female
Edema and
hemorrhagic
infarctions basal
ganglia, upper brain
stem, medial
temporal lobes,
frontal lobes, occipital
lobes
Decreased LOC, left
exotropia, unequal and
unreactive pupils,
papilledema
Quadriplegia, absent
oculocephalic reﬂexes,
central right facial
paresis, profound
cognitive defects
[15]
25 15 female
No cerebral edema in
ﬁrst 24 hours on CT.
Multiple small
hematomas,mainly
parieto-occipital, on
day 12MRI
First episode diabetes.
Signiﬁcant
hypotension,
unconscious at
presentation.
Neurologically normal
day 4. Bilateral knee
clonus, extensor
plantar response and
peripheral nerve palsies
on day 7
Decreased platelets
(85,000), normal
coagulation proﬁle
[23]
26 11 female
Normal MRI. On
autopsy: pin-point
hemorrhages with
ring-and-ball
morphology in
hemispheric white
matter, throughout
brainstem and spinal
cord
First presentation
diabetes, Hypotension,
rapid deterioration in
LOC
Death from renal
complications
Normal
coagulation studies [24]
27 14 female
Petechial
hemorrhages in B/L
subcortical white
matter U ﬁbers, genu
of corpus callosum,
posterior limb of
internal capsule,
frontal lobe on MRI
First presentation
diabetes, signiﬁcant
hypotension.
Unresponsive and
dyspneic
Short term memory
loss, moderate
cognitive deﬁcits
Normal
coagulation studies [24]
28 5 female Hemorrhagic infarct
left thalamus
First presentation
diabetes. Right central
facial palsy, right
hemiplegia, right
babinski sign on day 7
of treatment
Mild learning
diﬃculties
normal bleeding
studies, normal
protein C and S at
time of
hemorrhage
[25]
LOC: level of consciousness; B/L: bilateral;tPA: tissueplasminogen activator.6 Stroke Research and Treatment
Table 2: Coagulation abnormalities noted in cases of pediatric DKA with stroke and in studies of DKA-associated coagulopathy in adults
andchildren. Pretreatment abnormalitiesincludethosenoted priorto resolutionofbiochemical abnormalities.Posttreatmentabnormalities
include those noted after resolution of biochemical abnormalities.
Factor Parameter Pre-treatment
abnormality
Post-treatment
abnormality
Pediatric versus
adult study Relevant references
Platelet count
√√
pediatric [5, 14, 20, 23, 33]
aggregation/
activity
√√
pediatric, adult [5, 35, 39]
Thromboxane B2 production
√
pediatric [14]
Prothrombin time
√
pediatric [33]
Partial
thromboplastin
time
levels
√
pediatric [33]
Tissue Factor levels
√
adult [40]
vWF antigen level
√√
pediatric [14, 41]
activity
√
pediatric [41]
Factor VIII-vWF
complex levels
√
pediatric [14]
Factor V levels
√
pediatric [5]
Factor VII levels
√
pediatric [5]
Factor VIII levels
√
pediatric [5]
Homocysteine levels
√
pediatric [41]
Folate levels
√
pediatric [41]
Prothrombin
fragment 1 + 2 levels
√√
adult [35]
Thrombin-
antithrombin III
complex
levels
√√
adult [35]
Antithrombin III levels and activity
√√
pediatric, adult [5, 20, 33, 35]
Protein C activity
√
pediatric [41]
antigen level
√√
pediatric [14, 18, 41]
Protein S Free protein level
√
pediatric [42]
Thrombomodulin levels
√√
adult [35]
tPA activity
√
adult [35, 40]
antigen level
√√
adult [35, 40]
PAI-1 activity
√
adult [35, 40]
antigen level
√√
adult [35, 40]
vWF: von Willebrand Factor; tPA: tissueplasminogen activator; PAI-1: plasminogen activator inhibitor-1.
demonstrated, 1.4-times lower tPA secretion, 2.87-times
higher plasminogen activator inhibitor (PAI) activity, and
1.93-times higher PAI antigen level compared to baseline.
Combined, these ﬁndings suggest that impaired ﬁbrinolytic
activity is an early event in DKA. Furthermore, tissue factor
(TF), the primary initiator of coagulation, was signiﬁcantly
increased assoon astheinsulin infusion washalted.Noother
coagulation factor demonstrated altered serum levels, and it
i sn o ty e tc l e a rt h a tT Fp r o m o t e sp r o c o a g u l a n tc h a n g e si n
diabetic patients.
An examination of 34 adult patients with uncomplicated
DKA demonstrated evidence of endothelial injury, platelet
activation, relative hypoﬁbrinolysis, and activation of the
coagulation system, even in the absence of clinical signs of
thrombosis [35].Notsurprisingly, multivariate analysis indi-
cated that many of the endothelial, clinical, and hemostatic
factors were interrelated. Unlike the trial of insulin infusion
cessation [40], Ileri and colleagues found that ﬁbrinolytic
activity (tPA and plasmin-α2-antiplasmin complex levels)
was increased both before and during DKA treatment.
However, the upregulation was not to a degree expected for
the increase in coagulation activity (thrombin-antithrombin
III complex and prothrombin fragment 1 + 2 levels) at DKA
presentation. Not all alterations in the coagulation system
are procoagulant. Antithrombin III activity is generally
increased in T1DM. In contrast, at DKA presentation, levels
are slightly lower than baseline but are still higher than in a
control population [35].Stroke Research and Treatment 7
2.3. Platelet Numbers and Function. Increased platelet activ-
ity has been inconsistently demonstrated in children with
stroke [5], though no systematic studies of platelet activity
and aggregation have been performed in children during
DKA. Although platelet counts are generally normal in
T1DM, platelet function is enhanced both chronically [38]
and during an episode of DKA. Adult volunteers experienc-
ing acute hyperglycemia following an oral glucose challenge
demonstrate an acute increase in platelet aggregability [39].
It has been postulated that increased platelet activity may be
related to decreased nitric oxide availability reported during
episodes of DKA [52, 53]. Ileri and colleagues found that
platelet activation coexisted with DKA and was completely
normalized after recovery [35].
2.4. Blood Volume, Flow, and Vascular Reactivity. It has been
demonstrated in other conditions that dehydration alone
does not account for hypercoagulability [54]. Therefore,
although DKA may result in signiﬁcant ﬂuid losses, other
factors such as coagulation system abnormalities, hyper-
glycemia,acidemia-inducedredbloodcellrigidity(increased
blood viscosity) [55, 56], and vasoconstriction induced by
hyperglycemia may all have an additive role. The vascular
response in hyperglycemia has generally been considered
vasoconstrictive, and there is some evidence that this may be
relatedtodecreasedavailabilityofnitricoxide[53].However,
vascular endothelial growth factor expression is increased by
circulating ketones (β-hydroxybutyrate), leading to activity
of nitric oxide-guanylate cyclase pathway, and therefore
vasodilation, in mouse models [57]. Clinically, a transcranial
Doppler ultrasound study of 5 children with DKA demon-
strated signiﬁcant vascular dysregulation with vasodilation,
decreased cerebral blood ﬂow velocity, and loss of normal
cerebral blood ﬂow regulation that only normalized after
treatment [58]. Another group found normal to increased
cerebral blood ﬂow with impaired cerebral autoregulation
during episodes of DKA not associated with overt CE in 6
children [59]. Importantly, none ofthese studieswere able to
deﬁne the eﬀects that DKA has on local microvascular tone
and regulation, and therefore on cerebral oxygen delivery.
3.Pathogenesisof HemorrhagicStroke
While much of the above discussion has focused on the
pathogenesis of thrombosis, it is reasonable to suppose that
the pathophysiology of hemorrhagic stroke may involve
similar principles to that of hypoperfusion or thrombotic
stroke. During an episode of DKA, hemorrhage risk is
increased by endovascular perturbation secondary to the
proinﬂammatory state, and to hyperglycemia and acidosis
causing oxidative injury [24, 30, 31], as well as ischemic
injury to the vessels from cerebrovascular dysregulation [58,
59]orpr es en ta ti oni nas h ocks ta t e[24, 25].Inacase-control
study of 41 adult patients with hemorrhagic stroke, 31% of
diabetics had hemorrhagic conversion of infarcts compared
to 18% of nondiabetic stroke patients [60]. While these were
not in the setting of DKA, it does raise the possibility that
the aforementioned chronic inﬂammatory state that exists in
diabetes mellitus [27, 36] places these patients at higher risk
of hemorrhagic conversion of ischemic brain infarction.
DIC has been reported in children with DKA [33]. The
consumption of coagulation factors in DIC may predispose
to hemorrhage. Four cases of isolated intracerebral DIC,
including one case of a 3-month old (Table 1,p a t i e n t
1), have been reported [13, 34]. DIC was identiﬁed on
postmortem examination as wide-spread occlusion of small
vessels by thrombus, many of which were surrounded by
petechial hemorrhage. Furthermore, vascularmalformations
such as arteriovenous malformations (AVMs), aneurisms,
and cavernous malformations that predispose to stroke may
be relevant in this patient group. In children who experience
hemorrhagic stroke in the absence of diabetes mellitus,
vascular malformations are the most commonly experienced
risk factor, occurring in 20–85% in case series [61].
DKAisaproinﬂammatory conditionwithvascularendo-
thelial perturbation, and dysregulation of the coagulation
system features associated with abnormallevelsand activities
of several coagulation factors, including platelets, which
result in aprocoagulant state.Additionalfactorscontributing
to the procoagulant state are abnormalities in blood volume,
blood viscosity, cerebral autoregulation and blood ﬂow,
while vascular injury may be a result of oxidative injury and
ischemia related to systemic hypoperfusion, vascular dysreg-
ulation, or cerebral edema. Hemorrhagic stroke likely arises
secondary to hypoxia and the vascular injury encountered in
the oxidative, proinﬂammatory state of DKA.
4.Pathology: Ischemic versus
HemorrhagicStroke
We identiﬁed casesofstroke associated with DKAinchildren
and youth through an exhaustive search of the literature.
We searched PubMed for the following terms: [“stroke” or
“brain infarction” or “thrombosis”] and [“DKA”or“diabetic
ketoacidosis”]. Titles were hand searched for relevance, and
where signiﬁcance was unclear the abstract was read. All
appropriate articles were obtained and their reference lists
were scanned for other articles of relevance. This iterative
process was continued until no further new reports became
apparent. We have presented (Table 1)t h er e p o r t e dc a s e so f
DKA-associated stroke in the following categories: arterial
ischemic stroke [4–6, 14–16], cerebral venous thrombosis
[16–21],andhemorrhagicstroke[4,15,22–25].Basedonthe
limited investigative modalities available to those compiling
thereports, itislikelythatourabilitytodiﬀerentiatebetween
strokeetiologies(e.g.,arterial ischemia duetohypoperfusion
or thrombus, or hemorrhagic stroke with bleeding that arose
de novo versus secondary to bleeding within an ischemic
injury) is limited. This was clearly illustrated in the case
controlseriesdescribedbyMuirandcolleagues,inwhich 4of
23children with DKAwho had CTscanning after developing
clinical signs of cerebral edema demonstrated subarachnoid
or intraventricular hemorrhage without radiologic edema
[62]. Thus we determined that, where hemorrhage was
the only radiologic ﬁnding, the patient was included in
the “hemorrhagic stroke” group. The 4 patients from the
latter study were not included in Table 1,a st h e r ew a s8 Stroke Research and Treatment
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Figure 1: White matter hemorrhages associated with DKA. (a) This low-power view of a gyrus (stained with hematoxylin, eosin, and Luxol
fastblue)illustrates multiplesmallandmicroscopichemorrhages(arrowheads)associatedwith“conﬂuent”pallor(asterisks)ofthemyelin,a
thin layer of preserved subcortical myelin (arrows),and normalcortex. (b) A vessel, labeled V, is identiﬁed for reference. Stained with Luxol
fast blue, hematoxylin, and eosin (which stains myelin blue). Central hemorrhage was formed by perivascular necrosis (arrow), a concentric
ring of red blood cells, and diﬀusely rareﬁed white matter that is speckled with eosinophilic astrocytes (arrowheads). Figure 1 reproduced
with permissionfrom Pediatrics, volume 126, page 1543, copyright 2007 by the AAP.
no speciﬁc individual information given. Where multiple
small hemorrhages occurred in the setting of clear thrombus
or emboli [13], the patient was included in the “arterial
ischemic stroke” group. Cases of venous sinus thrombosis
with relevant clinical ﬁndings in the acutephase, butwith no
long-termclinicalorradiologic sequelae[16], were included,
as they represent acute intracerebral events associated with
DKA.
The pathologic tissue ﬁndings of a patient having experi-
enced acute cerebral infarction related to an episode of DKA
are not expected to be diﬀerent from those of a nondiabetic
child who has had a stroke. Two patients(patients26 and 27)
had hemorrhagic stroke that was characterized histologically
by a ring-and-ball morphology (Figure 1)[ 24]. Widespread
small vessel occlusion, diagnosed on autopsy, has also been
described [13]. As stroke itself may cause cerebral edema,
it becomes diﬃcult to ascertain whether cerebral edema in
DKA is the cause or an eﬀect of acute cerebral infarction.
Table 1 detailsthecourseoffourpatients(2,3,9,24)whohad
signs of raised intracranial pressure and may have suﬀered
cerebral hypoperfusion and infarction as a complication
o fD K A - C E .P a t i e n t s2 ,3 ,6 ,8 ,a n d2 8h a di n f a r c t i o n
limited to areas supplied by the posterior cerebral artery
and anterior choroidal arteries (the areas most susceptible
to damage following transtentorial herniation), presumably
secondary to raised intracranial pressure. However, some
of this group lacked clinical signs or radiological evidence
(patients 6,8,28) of CE, raising the possibility of a primary
thrombotic or hemorrhagic event. Patient 1 had signs of
DKA-CE but also clear thrombus formation on autopsy
[13].
Two patients were found to have thrombophilic con-
ditions. Patient 14 developed a DVT prior to presentation
with central nervous system complications of DKA. MRI
demonstratedacuteinfarctions inmultipleareas ofthebrain,
and examination identiﬁed heterozygosity for Factor V Lei-
den [18]. Patient 18, who developed thrombosis of multiple
cerebral venous sinuses, was found to have heterozygous
mutation of the prothrombin gene (G20210A) [21].
5.Evaluation
The clinical presentation of stroke as a focal neurologic
deﬁcit should pose little diagnostic problem. Of greater
diﬃculty is diﬀerentiating global neurological impairment
in DKA patients from severe acidosis, DKA-CE, or primary
stroke. Among the patients presented in Table 1,o n l y8
(patients 10,11,12,15,17,23,25,28) had focal neurologic
signs. The remainder presented with nonspeciﬁc signs
consistent with the global dysfunction seen in DKA-CE. As
t h ep r e s e n t a t i o no fC Ea n dp r i m a r ys t r o k ei nD K Ac a nb es o
similar, it is imperative that the clinician have a high index
of suspicion for stroke. Early imaging is warranted once the
patient is stabilized in order to optimize management.
The best modality for identiﬁcation of the ischemia
associated with stroke is magnetic resonance imaging (MRI)
with perfusion- and/or diﬀusion-weighted imaging, which
have sensitivity nearing 100% [63]. Computed tomography
(CT) may be used to rule out CE, hemorrhage or abscess,
though the sensitivity for identiﬁcation of ischemic infarc-
tion in the acute phase is only 50% [63]. Additionally, it is
agreed that CT may miss cases of cerebral edema, though
its sensitivity for identifying elevated intracranial pressure
has been reported at 99.1% [64]. Cerebral angiography is
the gold standard for assessment of the cerebral vasculature,
although MR angiography (MRA) is able to detect large
vascular lesions eﬀectively [65], with the beneﬁt of being
noninvasive. CT angiography, though it requires injection
of contrast, may be used to evaluate the cerebral circulation
early in stroke evolution [66]. In cases where neither MRA
nor MRI deﬁnes suspected pathology in a distal artery,
cerebral angiography may be considered.
Allpatientswith suspected intracranial pathologyshould
have a coagulation screen performed. In cases of clearStroke Research and Treatment 9
thrombosis or hemorrhage, more detailed analysis of the
hemostatic system is warranted. Identiﬁcation of the exact
histopathology may be done with tissue biopsy [24], though
this carries many risks and is not recommended as a matter
of course.
6.Management
Fully evidence-based management guidelines for children
experiencing acute ischemic or hemorrhagic infarction do
not exist and have been extrapolated from adult data.
Admission to the critical care unit and close monitoring is
appropriate for any patient with suspected or proven central
nervous system (CNS) complication of acute DKA. Unless
diﬀuse CE can be absolutely excluded,or another clear cause
is present, emergency management for CNS complications
of DKA should prioritize the treatment for cerebral edema.
Although early reactive treatment for CE appears beneﬁcial
[4, 67], it was stated in 1990 that intracerebral complications
do not often come with warning signs, and early inter-
vention measures are frequently unsuccessful in preventing
complications; so prevention of DKA is the most eﬀective
method of preventing complications [4]. In the intervening
20 years, this generally remains true, although there may be
some alternative management options for thrombus causing
stroke.
Children with stroke should receive aggressive treatment
for fever, infection, and seizures [68]. For all forms of
stroke, recommendations are for early mobilization and
rehabilitation. Current guidelines do not support the use
of thrombolytics in pediatric arterial ischemic stroke [69],
although thrombotic stroke associated with an episode of
DKAisnotaddressedspeciﬁcally.Furthermore,multiplecase
reports document use of thrombolytics treatment associated
with good outcome in children with acute ischemic cerebral
infarction [70–72], including thrombolysis used successfully
up to 36 hours after onset of symptoms [73, 74]. Safe, acute
thrombolysis with recombinant tPA was reported for a 10-
year-old child with cerebral venous sinus thrombosis that
occurred 3 days after onset of DKA, who had complete
recovery [21]. However, caution is warranted as the risks of
thrombolysis and the optimal tPA doses in children have not
been quantiﬁed. In light of the lack of evidence or strength
of recommendations, it seems prudent that management
of arterial ischemic stroke in association with DKA be
considered on a case-by-case basis and in consultation with
stroke experts.
Beyond the acute phase of ischemic or thrombotic
stroke it has generally been agreed that anticoagulation
with heparin [75, 76] may be appropriate for pediatric
patients who have already experienced arterial ischemic
stroke or cerebral venous thrombosis, independent of T1DM
and DKA. International guidelines recommend the use of
low molecular weight or unfractionated heparin initially,
followed by warfarin therapy for 3–6 months [75–77].
There is no clear guidance on the management of children
who have experienced hemorrhagic stroke. Adult guidelines
suggest that extremely high blood pressures be reduced
cautiously and recombinant factor VIIa has shown some
promise in decreasing recurrence but is only recommended
within clinical trials. However, these guidelines refer to
diﬀerentetiologiesforintracranial hemorrhage than are seen
in children or in the DKA population. Large hemorrhages
compromising neurovascular structures may warrant surgi-
cal decompression.
Prophylacticsystemicanticoagulationhasbeensuggested
for patients in DKA [13, 35, 78]. However, anticoagulation
is not addressed in international consensus statements on
the management of DKA [1, 79, 80]. In light of the risk of
hemorrhagic stroke and the unknown incidence of stroke
in pediatric DKA, a broad recommendation for prophylactic
anticoagulation cannot be supported at this time.
7.Outcome
Stroke outcome depends on the cerebral regions aﬀect and
the extent of the injury. As demonstrated from the case series
(Table 1), the majority of children with DKA-associated
stroke reported have some form of residual neurologic deﬁcit
with death or persistent vegetative state as the outcome in 8
of 28 patients (29%) and full recovery seen in only 4 of 28
cases (14%).
8.Conclusions
Stroke in DKA is uncommon but life-threatening. DKA
may be considered an inﬂammatory condition with vascular
endothelial perturbation and dysfunction of the coagulation
system. Multiple causes of thrombus have been postulated
and studies show several contributing mechanisms. Hem-
orrhagic infarctions are rare and may be multifactorial but
must be considered a risk. Management for CNS compli-
cations of DKA should prioritize the treatment for cerebral
edema. As the initial presentation of pediatric stroke can be
subtle and may be confused with DKA-CE, early imaging
for any young person with neurologic deterioration in
association with an episode of DKA is imperative following
emergency treatment for CE and stabilization.
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